Drug intelligence / Profile preview

Alfa Sincal

Development stage: Unknown
Lead developer: Sinsan Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Alfa Sincal** is an oral fixed-dose mineral and vitamin-D combination marketed by Sinsan Pharmaceuticals. The tablet contains **calcitriol, calcium carbonate, and zinc sulfate**. Calcitriol is the active form of vitamin D and activates the vitamin D receptor to increase intestinal calcium absorption and support calcium-phosphate homeostasis; calcium provides elemental calcium for bone mineralization, while zinc supports bone metabolism and tissue repair. It is used for calcium and vitamin-D deficiency and bone-health conditions including hypocalcemia, osteoporosis, renal osteodystrophy, hypoparathyroidism, rickets, and osteomalacia.

Brand names: Alfa Sincal

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Alfa Sincal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alfa Sincal.

Explore the full profile